PE20150891A1 - Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco - Google Patents

Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco

Info

Publication number
PE20150891A1
PE20150891A1 PE2015000568A PE2015000568A PE20150891A1 PE 20150891 A1 PE20150891 A1 PE 20150891A1 PE 2015000568 A PE2015000568 A PE 2015000568A PE 2015000568 A PE2015000568 A PE 2015000568A PE 20150891 A1 PE20150891 A1 PE 20150891A1
Authority
PE
Peru
Prior art keywords
alpha
antibody conjugates
receptor antibodies
drug antibody
antibodies
Prior art date
Application number
PE2015000568A
Other languages
English (en)
Spanish (es)
Inventor
Dangshe Ma
Fang Jin
Lioudmila Gennadievna Tchistiakova
Puja Sapra
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20150891A1 publication Critical patent/PE20150891A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2015000568A 2012-11-07 2013-10-30 Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco PE20150891A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261723545P 2012-11-07 2012-11-07
US201361749610P 2013-01-07 2013-01-07
US201361886156P 2013-10-03 2013-10-03
US201361889179P 2013-10-10 2013-10-10

Publications (1)

Publication Number Publication Date
PE20150891A1 true PE20150891A1 (es) 2015-06-11

Family

ID=49955428

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000568A PE20150891A1 (es) 2012-11-07 2013-10-30 Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco

Country Status (15)

Country Link
US (1) US9828428B2 (cg-RX-API-DMAC7.html)
EP (1) EP2916875A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016503295A (cg-RX-API-DMAC7.html)
KR (1) KR101763499B1 (cg-RX-API-DMAC7.html)
CN (1) CN104936621A (cg-RX-API-DMAC7.html)
AU (1) AU2013343111A1 (cg-RX-API-DMAC7.html)
CA (1) CA2890256A1 (cg-RX-API-DMAC7.html)
HK (1) HK1214161A1 (cg-RX-API-DMAC7.html)
IL (1) IL238566A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015005582A (cg-RX-API-DMAC7.html)
PE (1) PE20150891A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015500977A1 (cg-RX-API-DMAC7.html)
RU (1) RU2015116485A (cg-RX-API-DMAC7.html)
SG (1) SG11201503431TA (cg-RX-API-DMAC7.html)
WO (1) WO2014072888A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
HUE046249T2 (hu) * 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
EP3149024B9 (en) * 2014-05-28 2021-10-27 Agensys, Inc. Cytotoxic dolaproine-dolaisoleuine peptide derivatives for the treatment of cancer
RU2718692C2 (ru) 2014-05-29 2020-04-13 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016061562A2 (en) 2014-10-17 2016-04-21 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
EP4592311A2 (en) 2015-02-16 2025-07-30 Lonza Ltd Antibodies
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3-BINDING POLYPEPTIDES
TWI703160B (zh) * 2015-11-30 2020-09-01 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
CN107405408B (zh) * 2015-12-21 2021-07-02 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
WO2017162604A1 (en) 2016-03-21 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treatment of solar lentigo
US20200255524A1 (en) 2016-06-07 2020-08-13 Macrogenics, Inc. Combination therapy
CN108456250B (zh) 2017-02-17 2025-11-28 恺兴生命科技(上海)有限公司 靶向il-13ra2的抗体及其应用
CN107880131A (zh) * 2017-08-14 2018-04-06 四川大学 一种抗IL‑13Rα2和CD3双特异抗体及其应用
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
BR112020011810A2 (pt) 2017-12-12 2020-11-17 Macrogenics, Inc. molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
EP3752196A4 (en) 2018-02-15 2022-03-23 MacroGenics, Inc. CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
WO2019178085A1 (en) 2018-03-14 2019-09-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy
BR112020018670A2 (pt) 2018-03-14 2021-01-05 Seattle Children's Hospital (dba Seattle Children's Research Institute) Receptor de antígeno quimérico de receptor alfa 2 da il-13 (il13ra2) para imunoterapia com células t específicas para tumor
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
CN113423730B (zh) * 2019-02-15 2024-01-05 上海药明合联生物技术有限公司 用于制备具有改善的同质性的抗体-药物缀合物的方法
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20220144821A (ko) 2020-02-21 2022-10-27 마크로제닉스, 인크. Cd137 결합 분자 및 그것의 용도
JP2023525226A (ja) * 2020-05-15 2023-06-15 エリセラ セラピューティクス アクチエボラグ 抗ＩＬ１３Ｒα２抗体、その抗原結合フラグメントおよび使用
GB202011993D0 (en) * 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
WO2022174808A1 (zh) * 2021-02-19 2022-08-25 上海齐鲁制药研究中心有限公司 针对IL-13Rα2的抗体及其应用
JP2024527557A (ja) 2021-07-01 2024-07-25 寧波茂行生物医薬科技有限公司 Ｂ７ｈ３を標的とする抗原結合ポリペプチド及びその応用
US20240376216A1 (en) * 2021-07-01 2024-11-14 Ningbo T-Maximum Biopharmaceuticals Co., Ltd. Universal car-t cell targeting il13ralpha2, preparation method therefor and application thereof
PE20250351A1 (es) * 2022-02-17 2025-02-06 Lanova Medicines Dev Co Ltd Anticuerpos monoclonales anti-il-13ra2 y sus usos
EP4577575A1 (en) * 2022-08-25 2025-07-02 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
CN115960257B (zh) * 2022-09-29 2023-10-27 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的经优化的嵌合抗原受体及其用途
JPWO2024071397A1 (cg-RX-API-DMAC7.html) * 2022-09-30 2024-04-04

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2002017968A2 (en) 2000-08-31 2002-03-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
WO2005042028A2 (en) 2003-10-27 2005-05-12 Neopharm, Inc. Il-13 conjugated to an immunogen and uses thereof
AU2007319605B2 (en) 2006-10-19 2011-02-17 Csl Limited Anti-IL-13R alpha 1 antibodies and their uses thereof
AU2007319604B2 (en) 2006-10-19 2011-03-24 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
JP2010190572A (ja) 2007-06-01 2010-09-02 Sapporo Medical Univ ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬
CA2804185C (en) 2010-07-12 2017-03-21 Covx Technologies Ireland Limited Multifunctional antibody conjugates
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
TW201341401A (zh) 2012-01-09 2013-10-16 Covx Technologies Ireland Ltd 突變抗體及其共軛

Also Published As

Publication number Publication date
KR20150060980A (ko) 2015-06-03
MX2015005582A (es) 2015-08-14
KR101763499B1 (ko) 2017-07-31
PH12015500977A1 (en) 2015-07-13
CN104936621A (zh) 2015-09-23
SG11201503431TA (en) 2015-05-28
WO2014072888A1 (en) 2014-05-15
CA2890256A1 (en) 2014-05-15
HK1214161A1 (zh) 2016-07-22
US9828428B2 (en) 2017-11-28
JP2016503295A (ja) 2016-02-04
IL238566A0 (en) 2015-06-30
EP2916875A1 (en) 2015-09-16
US20150266962A1 (en) 2015-09-24
RU2015116485A (ru) 2016-12-27
AU2013343111A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
PE20150891A1 (es) Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco
IL272304A (en) Bcma monoclonal antibody-drug conjugate
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
PL3626825T3 (pl) Przeciwciało anty-cdh6 i koniugat przeciwciała anty-cdh6 z lekiem
HUE056289T2 (hu) Pirrolobenzodiazepin-antitest konjugátumok
PL3515487T3 (pl) Dwuswoiste przeciwciała anty-muc16-cd3 oraz koniugaty przeciwciało anty-muc16 - lek
CO6720984A2 (es) Anticuerpos anti-mesotelina e inmunoconjugados
PE20151926A1 (es) Anticuerpos de receptores de antitransferrina y metodos de uso
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
DK3504241T3 (da) Anti-cd3-antistofformuleringer
DK3544636T3 (da) Pyrrolobenzodiazepin-antistof-konjugater
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
CR20140441A (es) Anticuerpos anti-lgr5 e inmunoconjugados
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
EP2953643A4 (en) NON-PLATE DEPLETING AND NON-ERYTHROCYTE DEPLETING CD47 ANTIBODIES AND METHOD FOR USE THEREOF
CO6771458A2 (es) Conjugados de anticuerpo-fármaco
EP3580239A4 (en) ANTIBODY ANTI-ILT3 AND ANTIBODY-DRUG CONJUGATES
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso

Legal Events

Date Code Title Description
FD Application declared void or lapsed